Kymera Therapeutics (KYMR) FCF Margin (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly FCF Margin of 259.78% for Q1 2026, up 10048.0% year-over-year from N/an in Q1 2025, and up 89.73% quarter-over-quarter from 2528.5% in Q4 2025.
Powered by 
Analysis
Kymera Therapeutics (KYMR) FCF Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported FCF Margin for 8 consecutive years, with 259.78% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 10048.0% year-over-year to 259.78%; the TTM figure through Mar 2026 stood at 485.11% (down 7760.0% YoY), while the FY2025 annual figure was 612.21%, down 17174.0% from the prior year.
- FCF Margin climbed to 259.78% in Q1 2026 per KYMR's latest filing, from 2528.5% in the prior quarter.
- Across five years, FCF Margin topped out at 18.7% in Q4 2023 and bottomed at 2528.5% in Q4 2025.
- Historically, FCF Margin has averaged 587.72% across 5 years, with a median of 371.85% in 2022.
- On a YoY basis, FCF Margin climbed as much as 34919 bps in 2025 and fell as far as 168025 bps in 2025.
- Kymera Therapeutics' FCF Margin stood at 235.89% in 2022, then jumped by 108 bps to 18.7% in 2023, then slumped by 4636 bps to 848.26% in 2024, then slumped by 198 bps to 2528.5% in 2025, then jumped by 90 bps to 259.78% in 2026.
- Business Quant data shows KYMR's FCF Margin at 259.78% in Q1 2026, 2528.5% in Q4 2025, and 987.37% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - | -79.85% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -79.85% |
| Mar 31, 2026 | -259.78% |
| Dec 31, 2025 | -2,528.50% |
| Sep 30, 2025 | -930.82% |
| Jun 30, 2025 | -541.50% |
| Mar 31, 2025 | -360.26% |
| Dec 31, 2024 | -848.26% |
| Sep 30, 2024 | -1,336.57% |
| Jun 30, 2024 | -185.67% |
| Mar 31, 2024 | -456.82% |
| Dec 31, 2023 | -7.48% |
| Sep 30, 2023 | -840.21% |
| Jun 30, 2023 | -278.71% |
| Mar 31, 2023 | -506.83% |
| Dec 31, 2022 | -247.28% |
| Sep 30, 2022 | -371.85% |
| Jun 30, 2022 | -344.97% |
| Mar 31, 2022 | -423.79% |
| Dec 31, 2021 | -256.94% |
| Sep 30, 2021 | -184.73% |